Trial Profile
A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2014
Price :
$35
*
At a glance
- Drugs Cipargamin (Primary)
- Indications Falciparum malaria; Vivax malaria
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 31 Jul 2014 Results published in the New England Journal of Medicine.
- 30 Jul 2014 Results have been published in New England Journal of Medicine, according to a Novartis media release.
- 11 Jun 2014 New trial record